in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Director — Elliott Levy, M.D.: Dr. Elliott Levy resigned from the Board and was succeeded by Dr. Patrick Ellinor.

Other Events. The full text of the press release announcing the pricing of the underwritten public offering on May 26, 2026 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Cash Runway Based upon the Company’s current plans and forecasted expenses, the Company estimates that the net proceeds from the underwritten offering, together with the Company’s cash and cash equivalents as of March 31, 2026, will enable the Company to fund its operations into the second half o…

Entry into a Material Definitive Agreement. Public Offering On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 55,555,556 shares (the “Underwritten Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), an…

Other Events. On May 26, 2026, Editas Medicine, Inc. (the “Company”) notified TD Securities (USA) LLC (“TD Cowen”) that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company entered into with TD Cowen on May 14, 2021, as amended on February 28, 2024 and on March 5, 2025 (as amended, the “Sales Agreement”), and pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (th…

Other Events. On May 25, 2026, the Company announced in an oral presentation at the 94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development candidate, from preclinical studies in non-human primates (“NHPs”). In the data presented, EDIT-401 achieved robust reductions in LDL-cholesterol (“LDL-C”), lipoprotein(a) (“Lp(a)”), and apolipoprotein B (“ApoB”). The findings presented included: · A single dose of EDIT-401 achieved a 90% or gr…

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On April 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Editas Medicine, Inc. (the “Company”) (i) dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, effective immediately, and (ii) appointed PricewaterhouseCoopers LLP (“PwC”) to serve as the Company’s new independent registered public account…

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events. Nomination of Lead Development Candidate On September 2, 2025, the Company announced the nomination of its lead in vivo development candidate, EDIT-401, a therapy designed to reduce LDL cholesterol (“LDL-C”) levels. EDIT-401 is an experimental in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. This targeted…

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The filing describes an amendment and restatement of the Company's stock incentive plan, which is not a management change event.

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

CFO — Erick Lucera: Mr. Lucera resigned as CFO, and Ms. Parison was appointed as the new CFO.

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K is unaudited and preliminary, subject to the completion of the Company’s fourth quarter and fiscal year financial closing procedures, and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2024 or the results of operations for the three months or fiscal year ended December 31, 2024. The Financial Information may differ materially from the amounts that will be reflected in the Company’s cons…

Costs Associated with Exit or Disposal Activities. On December 11, 2024, the board of directors (the “Board”) of Editas Medicine, Inc. (the “Company”) approved the discontinuation of the clinical development of the Company's ex vivo renizgamglogene autogedtemcel (“reni-cel”) program (the “Discontinuation”) to treat sickle cell disease and transfusion-dependent beta thalassemia. In connection with the Discontinuation, the Board approved a reduction in the Company’s employee workforce by approx…

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K is unaudited and preliminary, subject to the completion of the Company’s third quarter financial closing procedures, and does not present all information necessary for an understanding of the Company’s financial condition as of September 30, 2024 or the results of operations for the three or nine months ended September 30, 2024. The Financial Information may differ materially from the amounts that will be reflected in the Company’s consolidated financial sta…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On October 3, 2024, Editas Medicine, Inc. (the “Company”) entered into a purchase and sale agreement (the “Purchase and Sale Agreement”) with a wholly-owned subsidiary of DRI Healthcare Trust (the “Purchaser”) providing for an upfront cash payment by the Purchaser to the Company of $57.0 million in exchange for the acquisition by the Purchaser of certain future license fees and other payments (the “Purchased Receivables”) owed to the Company by Vert…

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Director — Akshay Vaishnaw: Dr. Akshay Vaishnaw resigned from the Board of Directors.

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.